Evidence map›Paper›PMID 40667360›Full record

ArticlebioRxiv : the preprint server for biology2025

Spatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma.

Tuulia Vallius, Yingxiao Shi, Edward Novikov, Shishir M Pant, Roxanne Pelletier, Yu-An Chen, Juliann B Tefft, Ajit Nirmal Johnson, Zoltan Maliga, Guihong Wan and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tuulia ValliusLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3006-4887
Yingxiao ShiLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-2783-9642
Edward NovikovLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-1476-5111
Shishir M PantLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-2686-7898
Roxanne PelletierLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-1957-5483
Yu-An ChenLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0001-7228-4696
Juliann B TefftLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-8826-665X
Ajit Nirmal JohnsonLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4139-0618
Zoltan MaligaLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4209-7253
Guihong WanLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-1100-4018
George MurphyProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115.ORCID 0000-0001-9362-5146
Sandro SantagataLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-7528-9668
Yevgeniy R SemenovLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-7387-3094
David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0003-0346-5033
Christine G LianProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115.ORCID 0000-0003-4626-1612
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3364-1838

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO · 2018 to 2023
$8.7M
High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapyR50CA252138 · NCI · HARVARD MEDICAL SCHOOL · PI MALIGA, ZOLTAN · 2020 to 2024
$1.0M
Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial ModelingR00CA256497 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NIRMAL, AJIT JOHNSON · 2023 to 2025
$747k
NCI NIH HHS P30 CA006516NCI NIH HHS R00 CA256497NCI NIH HHS R50 CA252138NCI NIH HHS U2C CA233262
6 · The paper itself

Abstract

Early detection of melanoma through skin surveillance is critical for preventing metastatic progression. Primary cutaneous melanomas at early stage offer a unique opportunity to uncover fundamental mechanisms of tumor initiation, progression, and immune surveillance, but detailed spatial profiling of early disease remains limited. Here we integrate high-plex cyclic immunofluorescence (CyCIF) imaging, spatial transcriptomics, and conventional histology to identify factors associated with de-differentiation and dermal invasion in early-stage melanomas. We demonstrate a high level of variability from one primary cancer to the next, from one 100-300 cell microregion to the next within a single cancer, and from one cell to the next within a microregion. Intra-tumoral heterogeneity is influenced by local features of the microenvironment including proximity to T and myeloid cells and to perivascular environments. Thus, tumor plasticity and spatial heterogeneity arise early in melanoma development, potentially allowing for competition among multiple tumor states during the emergence of invasive disease.

Indexed as

cancer progressioncell state switchCutaneous melanomadedifferentiationintratumor heterogeneitylineage plasticitymelanoma heterogeneitymultiplex imagingspatial transcriptomicsspatial variance

Identifiers

PMID40667360
PMCPMC12262277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.